O	0	7	Patient
O	7	8	-
O	8	16	reported
O	17	25	outcomes
O	26	30	from
O	31	37	EMILIA
O	37	38	,
O	39	40	a
O	41	51	randomized
O	52	57	phase
O	58	59	3
O	60	65	study
O	66	68	of
B-intervention	69	80	trastuzumab
I-intervention	81	90	emtansine
I-intervention	91	92	(
I-intervention	92	93	T
I-intervention	93	94	-
I-intervention	94	97	DM1
I-intervention	97	98	)
O	99	105	versus
B-control	106	118	capecitabine
I-control	119	122	and
I-control	123	132	lapatinib
O	133	135	in
O	136	141	human
O	142	151	epidermal
O	152	158	growth
O	159	165	factor
O	166	174	receptor
O	175	176	2
O	176	177	-
O	177	185	positive
O	186	193	locally
O	194	202	advanced
O	203	205	or
O	206	216	metastatic
O	217	223	breast
O	224	230	cancer
O	230	231	.

O	232	236	This
O	237	243	report
O	244	253	describes
O	254	257	the
O	258	265	results
O	266	268	of
O	269	271	an
O	272	280	analysis
O	281	283	of
O	284	291	patient
O	291	292	-
O	292	300	reported
O	301	309	outcomes
O	310	314	from
O	315	321	EMILIA
O	322	323	(
O	323	331	TDM4370g
O	331	332	/
O	332	339	BO21977
O	339	340	)
O	340	341	,
O	342	343	a
O	344	354	randomized
O	355	360	phase
O	361	362	3
O	363	368	study
O	369	371	of
O	372	375	the
O	376	384	antibody
O	384	385	-
O	385	389	drug
O	390	399	conjugate
O	400	411	trastuzumab
O	412	421	emtansine
O	422	423	(
O	423	424	T
O	424	425	-
O	425	428	DM1
O	428	429	)
O	430	436	versus
O	437	449	capecitabine
O	450	453	and
O	454	463	lapatinib
O	464	466	in
O	467	472	human
O	473	482	epidermal
O	483	489	growth
O	490	496	factor
O	497	505	receptor
O	506	507	2
O	508	509	(
O	509	513	HER2
O	513	514	)
O	514	515	-
O	515	523	positive
O	524	531	locally
O	532	540	advanced
O	541	543	or
O	544	554	metastatic
O	555	561	breast
O	562	568	cancer
O	568	569	.

O	570	571	A
O	572	581	secondary
O	582	590	endpoint
O	591	593	of
O	594	597	the
O	598	604	EMILIA
O	605	610	study
O	611	614	was
B-outcome-Measure	615	619	time
I-outcome-Measure	620	622	to
I-outcome-Measure	623	630	symptom
I-outcome-Measure	631	640	worsening
O	641	642	(
O	642	646	time
O	647	651	from
O	652	665	randomization
O	666	668	to
O	669	672	the
O	673	678	first
O	679	692	documentation
O	693	695	of
O	696	697	a
O	698	699	≥
O	700	701	5
O	701	702	-
O	702	707	point
O	708	716	decrease
O	717	721	from
O	722	730	baseline
O	730	731	)
O	732	734	as
O	735	743	measured
O	744	746	by
O	747	750	the
O	751	756	Trial
O	757	764	Outcome
O	765	770	Index
O	771	779	Physical
O	779	780	/
O	780	790	Functional
O	790	791	/
O	791	797	Breast
O	798	799	(
O	799	802	TOI
O	802	803	-
O	803	806	PFB
O	806	807	)
O	808	814	subset
O	815	817	of
O	818	821	the
O	822	832	Functional
O	833	843	Assessment
O	844	846	of
O	847	853	Cancer
O	854	861	Therapy
O	861	862	-
O	862	868	Breast
O	869	882	questionnaire
O	882	883	.

O	884	894	Predefined
O	895	906	exploratory
O	907	914	patient
O	914	915	-
O	915	923	reported
O	924	931	outcome
O	932	941	endpoints
O	942	950	included
O	951	961	proportion
O	962	964	of
O	965	973	patients
O	974	978	with
O	979	980	a
O	981	991	clinically
O	992	1003	significant
O	1004	1015	improvement
O	1016	1018	in
O	1019	1027	symptoms
O	1028	1029	(
O	1029	1032	per
O	1033	1036	TOI
O	1036	1037	-
O	1037	1040	PFB
O	1040	1041	)
O	1042	1045	and
O	1046	1056	proportion
O	1057	1059	of
O	1060	1068	patients
O	1069	1073	with
O	1074	1082	diarrhea
O	1083	1091	symptoms
O	1092	1093	(
O	1093	1096	per
O	1097	1105	Diarrhea
O	1106	1116	Assessment
O	1117	1122	Scale
O	1122	1123	)
O	1123	1124	.

O	1125	1127	In
O	1128	1131	the
O	1132	1133	T
O	1133	1134	-
O	1134	1137	DM1
O	1138	1141	arm
O	1141	1142	,
B-iv-bin-abs	1143	1146	450
O	1147	1149	of
B-intervention-participants	1150	1153	495
O	1154	1162	patients
O	1163	1166	had
O	1167	1168	a
O	1169	1177	baseline
O	1178	1181	and
O	1182	1183	≥
O	1184	1185	1
O	1186	1198	postbaseline
B-outcome	1199	1202	TOI
I-outcome	1202	1203	-
I-outcome	1203	1206	PFB
I-outcome	1207	1212	score
O	1213	1219	versus
B-cv-bin-abs	1220	1223	445
O	1224	1226	of
B-control-participants	1227	1230	496
O	1231	1239	patients
O	1240	1242	in
O	1243	1246	the
O	1247	1259	capecitabine
O	1259	1260	-
O	1260	1264	plus
O	1264	1265	-
O	1265	1274	lapatinib
O	1275	1278	arm
O	1278	1279	.

B-outcome	1280	1284	Time
I-outcome	1285	1287	to
I-outcome	1288	1295	symptom
I-outcome	1296	1305	worsening
O	1306	1309	was
O	1310	1317	delayed
O	1318	1320	in
O	1321	1324	the
O	1325	1326	T
O	1326	1327	-
O	1327	1330	DM1
O	1331	1334	arm
O	1335	1341	versus
O	1342	1345	the
O	1346	1358	capecitabine
O	1358	1359	-
O	1359	1363	plus
O	1363	1364	-
O	1364	1373	lapatinib
O	1374	1377	arm
O	1378	1379	(
B-iv-cont-median	1379	1380	7
I-iv-cont-median	1380	1381	.
I-iv-cont-median	1381	1382	1
I-iv-cont-median	1383	1389	months
O	1390	1396	versus
B-cv-cont-median	1397	1398	4
I-cv-cont-median	1398	1399	.
I-cv-cont-median	1399	1400	6
I-cv-cont-median	1401	1407	months
O	1407	1408	,
O	1409	1421	respectively
O	1421	1422	;
O	1423	1429	hazard
O	1430	1435	ratio
O	1436	1437	=
O	1438	1439	0
O	1439	1440	.
O	1440	1443	796
O	1443	1444	;
O	1445	1446	P
O	1447	1448	=
O	1449	1450	.
O	1450	1454	0121
O	1454	1455	)
O	1455	1456	.

O	1457	1459	In
O	1460	1463	the
O	1464	1465	T
O	1465	1466	-
O	1466	1469	DM1
O	1470	1473	arm
O	1473	1474	,
B-iv-bin-percent	1475	1477	55
I-iv-bin-percent	1477	1478	.
I-iv-bin-percent	1478	1479	3
I-iv-bin-percent	1479	1480	%
O	1481	1483	of
O	1484	1492	patients
O	1493	1502	developed
B-outcome	1503	1513	clinically
I-outcome	1514	1525	significant
I-outcome	1526	1537	improvement
I-outcome	1538	1540	in
I-outcome	1541	1549	symptoms
O	1550	1554	from
O	1555	1563	baseline
O	1564	1570	versus
B-cv-bin-percent	1571	1573	49
I-cv-bin-percent	1573	1574	.
I-cv-bin-percent	1574	1575	4
I-cv-bin-percent	1575	1576	%
O	1577	1579	in
O	1580	1583	the
O	1584	1596	capecitabine
O	1596	1597	-
O	1597	1601	plus
O	1601	1602	-
O	1602	1611	lapatinib
O	1612	1615	arm
O	1616	1617	(
O	1617	1618	P
O	1619	1620	=
O	1621	1622	.
O	1622	1626	0842
O	1626	1627	)
O	1627	1628	.

O	1629	1637	Although
O	1638	1645	similar
O	1646	1648	at
O	1649	1657	baseline
O	1657	1658	,
O	1659	1662	the
O	1663	1669	number
O	1670	1672	of
O	1673	1681	patients
O	1682	1691	reporting
O	1692	1700	diarrhea
O	1701	1709	symptoms
O	1710	1719	increased
O	1720	1721	1
O	1721	1722	.
O	1722	1723	5
O	1723	1724	-
O	1725	1727	to
O	1728	1729	2
O	1729	1730	-
O	1730	1734	fold
O	1735	1741	during
O	1742	1751	treatment
O	1752	1756	with
O	1757	1769	capecitabine
O	1770	1773	and
O	1774	1783	lapatinib
O	1784	1787	but
O	1788	1796	remained
O	1797	1801	near
O	1802	1810	baseline
O	1811	1817	levels
O	1818	1820	in
O	1821	1824	the
O	1825	1826	T
O	1826	1827	-
O	1827	1830	DM1
O	1831	1834	arm
O	1834	1835	.

O	1836	1844	Together
O	1845	1849	with
O	1850	1853	the
O	1854	1860	EMILIA
O	1861	1868	primary
O	1869	1873	data
O	1873	1874	,
O	1875	1880	these
O	1881	1888	results
O	1889	1896	support
O	1897	1900	the
O	1901	1908	concept
O	1909	1913	that
O	1914	1915	T
O	1915	1916	-
O	1916	1919	DM1
O	1920	1923	has
O	1924	1931	greater
O	1932	1940	efficacy
O	1941	1944	and
O	1945	1957	tolerability
O	1958	1962	than
O	1963	1975	capecitabine
O	1976	1980	plus
O	1981	1990	lapatinib
O	1990	1991	,
O	1992	1997	which
O	1998	2001	may
O	2002	2011	translate
O	2012	2016	into
O	2017	2029	improvements
O	2030	2032	in
O	2033	2039	health
O	2039	2040	-
O	2040	2047	related
O	2048	2055	quality
O	2056	2058	of
O	2059	2063	life
O	2063	2064	.
